JP2022546686A5 - - Google Patents
Info
- Publication number
- JP2022546686A5 JP2022546686A5 JP2022512775A JP2022512775A JP2022546686A5 JP 2022546686 A5 JP2022546686 A5 JP 2022546686A5 JP 2022512775 A JP2022512775 A JP 2022512775A JP 2022512775 A JP2022512775 A JP 2022512775A JP 2022546686 A5 JP2022546686 A5 JP 2022546686A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893838P | 2019-08-30 | 2019-08-30 | |
| US62/893,838 | 2019-08-30 | ||
| PCT/EP2020/074186 WO2021038097A1 (en) | 2019-08-30 | 2020-08-31 | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546686A JP2022546686A (ja) | 2022-11-07 |
| JP2022546686A5 true JP2022546686A5 (https=) | 2023-08-30 |
| JPWO2021038097A5 JPWO2021038097A5 (https=) | 2023-08-30 |
Family
ID=72322444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512775A Pending JP2022546686A (ja) | 2019-08-30 | 2020-08-31 | 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12599620B2 (https=) |
| EP (1) | EP4021457A1 (https=) |
| JP (1) | JP2022546686A (https=) |
| CN (1) | CN114980901A (https=) |
| AU (1) | AU2020339737A1 (https=) |
| CA (1) | CA3149049A1 (https=) |
| WO (1) | WO2021038097A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| US6713054B1 (en) * | 1998-10-07 | 2004-03-30 | Cira Technologies, Inc. | Cellular immunotherapy treatment of patients afflicted with chronic fatigue syndrome |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US20110142836A1 (en) * | 2009-01-02 | 2011-06-16 | Olav Mella | B-cell depleting agents for the treatment of chronic fatigue syndrome |
| WO2016102530A1 (en) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| RU2018114459A (ru) * | 2015-09-21 | 2019-10-23 | Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре | Новые стратегии лечения рака крови |
| CN108601767A (zh) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
-
2020
- 2020-08-31 AU AU2020339737A patent/AU2020339737A1/en active Pending
- 2020-08-31 CA CA3149049A patent/CA3149049A1/en active Pending
- 2020-08-31 CN CN202080074892.3A patent/CN114980901A/zh active Pending
- 2020-08-31 US US17/638,453 patent/US12599620B2/en active Active
- 2020-08-31 JP JP2022512775A patent/JP2022546686A/ja active Pending
- 2020-08-31 EP EP20764981.5A patent/EP4021457A1/en active Pending
- 2020-08-31 WO PCT/EP2020/074186 patent/WO2021038097A1/en not_active Ceased